Results 21 to 30 of about 49,135 (301)

Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation [PDF]

, 2013
OBJECTIVE: In clinical trials of dabigatran and rivaroxaban for stroke prevention in atrial fibrillation (AF), drug eligibility and dosing were determined using the Cockcroft-Gault equation to estimate creatine clearance as a measure of renal function ...
Ashman, N, Green, L, Hull, SA, MacCallum, PK, Mathur, R, Morris, JK, Saja, K   +6 more
core   +3 more sources

Direct Thrombin Inhibitor Dabigatran Compromises Pulmonary Endothelial Integrity in a Murine Model of Breast Cancer Metastasis to the Lungs; the Role of Platelets and Inflammation-Associated Haemostasis

Frontiers in Pharmacology, 2022
Activation of the coagulation cascade favours metastatic spread, but antithrombotic therapy might also have detrimental effects on cancer progression. In this study, we characterized the effects of dabigatran, a direct reversible thrombin inhibitor, on ...
M. Smęda, M. Stojak, K. Przyborowski, M. Sternak, Joanna Suraj‐Prażmowska, K. Kuś, K. Derszniak, A. Jasztal, A. Kij, Anna Kurpińska, Anna Kieronska-Rudek, K. Wojnar-Lason, E. Buczek, T. Mohaissen, S. Chłopicki   +14 more
semanticscholar   +1 more source

Impact of Dabigatran Treatment on Rotation Thromboelastometry

Clinical and Applied Thrombosis/Hemostasis, 2021
A rapid and reliable assessment of the dabigatran effect is desirable in dabigatran treated patients with uncontrolled bleeding or before acute surgery.
Juraj Sokol MD, PhD, Frantisek Nehaj MD, Jela Ivankova RNDr, Michal Mokan MD, PhD, Jana Zolkova RNDr, Lenka Lisa MD, PhD, Ludmila Linekova MD, Marian Mokan MD, DSc, FRCP Edin, Jan Stasko MD, PhD   +8 more
doaj   +1 more source

Recanalization after cerebral venous thrombosis. A randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous and dural sinus thrombosis

International Journal of Stroke, 2021
Background The effect of different anticoagulants on recanalization after cerebral venous thrombosis has not been studied in a randomized controlled trial.
J. Ferro, M. Bendszus, O. Jansen, J. Coutinho, F. Dentali, A. Kobayashi, D. Aguiar de Sousa, L. Neto, C. Miede, Jorge Caria, H. Huisman, H. Diener   +11 more
semanticscholar   +1 more source

The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects

Pharmacogenomics and Personalized Medicine, 2021
Dabigatran is a novel direct oral anticoagulant agent, whose plasma concentration is closely related to bleeding risk. Genetic polymorphisms can affect the level of plasma dabigatran.
Yue Liu, Chenguang Yang, Wenyuan Qi, Zuowei Pei, W. Xue, Huolan Zhu, Min Dong, Yingqiao Guo, Duanduan Cong, Fang Wang   +9 more
semanticscholar   +1 more source

Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source

New England Journal of Medicine, 2019
Background Cryptogenic strokes constitute 20 to 30% of ischemic strokes, and most cryptogenic strokes are considered to be embolic and of undetermined source.
H. Diener, R. Sacco, D. Easton, C. Granger, R. Bernstein, S. Uchiyama, J. Kreuzer, Lisa Cronin, D. Cotton, Claudia Grauer, M. Brueckmann, M. Chernyatina, G. Donnan, J. Ferro, M. Grond, B. Kallmünzer, J. Krupiński, Byung‐Chul Lee, R. Lemmens, J. Masjuán, M. Odinak, J. Saver, P. Schellinger, D. Toni, K. Toyoda   +24 more
semanticscholar   +1 more source

Alzheimer’s Disease—Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran

International Journal of Molecular Sciences, 2021
Alzheimer’s disease (AD) is caused by neurodegenerative, but also vascular and hemostatic changes in the brain. The oral thrombin inhibitor dabigatran, which has been used for over a decade in preventing thromboembolism and has a well-known ...
K. Grossmann
semanticscholar   +1 more source

The Dabigatran debate

Global Cardiology Science and Practice, 2014
In the June 2013 issue of this Journal, we described compelling evidence for the use of three novel anticoagulants, including Dabigatran, on the basis of recent large multi-centre trials.1 We acknowledged the approval of NOACs over warfarin in the ESC update and ACCP guidelines, and foresaw the greater usage of these newer, promising, therapies for ...
Kaba, Riyaz A, Ara, Farhana, Ward, David E, Emanuel, Subo   +3 more
openaire   +2 more sources

Safety of Dabigatran as an Anticoagulant: A Systematic Review and Meta-Analysis

Frontiers in Pharmacology, 2021
Background: Dabigatran is a univalent low-molecular-weight direct thrombin inhibitor which was developed as an alternative to vitamin K antagonists (VKAs). However, the safety of dabigatran remains controversial so far. In this study, we aimed to compare
Ya Zhou, Zhihao Yao, Linjie Zhu, Yong Tang, Jie Chen, Jianming Wu   +5 more
semanticscholar   +1 more source

Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non-valvular atrial fibrillation

Journal of Arrhythmia, 2015
Background: Activated partial thromboplastin time (aPTT) is recommended for monitoring anticoagulant activity in dabigatran-treated patients; however, there are limited data in Japanese patients.
Daiki Shimomura, Yoshihisa Nakagawa, MD, Hirokazu Kondo, MD, Toshihiro Tamura, MD, Masashi Amano, MD, Yukiko Hayama, MD, Naoaki Onishi, MD, Yodo Tamaki, MD, Makoto Miyake, MD, Kazuaki Kaitani, MD, Chisato Izumi, MD, Masahiko Hayashida, Aya Fukuda, Fumihiko Nakamura, MD, Seiji Kawano, MD   +14 more
doaj   +1 more source